ESR1 Antibody

Code CSB-PA11399A0Rb
Size US$299Purchase it in Cusabio online store
(only available for customers from the US)
  • Western blot
    All lanes: ESR1 antibody at 7µg/ml
    Lane 1: Hela whole cell lysate
    Lane 2: MCF-7 whole cell lysate
    Lane 3: Rat brain tissue
    Lane 4: Colo320 whole cell lysate
    Goat polyclonal to rabbit IgG at 1/10000 dilution
    Predicted band size: 67, 54, 48, 36 kDa
    Observed band size: 67 kDa

  • Immunohistochemistry of paraffin-embedded human breast cancer using CSB-PA11399A0Rb at dilution of 1:100

  • Chromatin Immunoprecipitation MCF-7 (1.1*106) were cross-linked with formaldehyde, sonicated, and immunoprecipitated with 4µg anti-ESR1 or a control normal rabbit IgG. The resulting ChIP DNA was quantified using real-time PCR with primers (CSB-PP11399HU) against the ESR1 promoter.

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) ESR1 Polyclonal antibody
Uniprot No. P03372
Target Names ESR1
Alternative Names 7*/654 isoform antibody; 7*/819 2 isoform antibody; 7*/822 isoform antibody; 8*/901 isoform antibody; 8*/941 isoform antibody; DKFZp686N23123 antibody; ER alpha antibody; ER antibody; ER-alpha antibody; Era antibody; ESR antibody; ESR1 antibody; ESR1_HUMAN antibody; ESRA antibody; Estradiol receptor antibody; Estrogen nuclear receptor alpha antibody; Estrogen receptor 1 antibody; Estrogen receptor alpha 3*,4,5,6,7*/822 isoform antibody; Estrogen receptor alpha antibody; Estrogen receptor alpha delta 3*,4,5,6,7*,8*/941 isoform antibody; Estrogen receptor alpha delta 3*,4,5,6,7*/819 2 isoform antibody; Estrogen receptor alpha delta 4 +49 isoform antibody; Estrogen receptor alpha delta 4*,5,6,7*/654 isoform antibody; Estrogen receptor alpha delta 4*,5,6,7,8*/901 isoform antibody; Estrogen receptor alpha E1 E2 1 2 antibody; Estrogen receptor alpha E1 N2 E2 1 2 antibody; Estrogen receptor antibody; ESTRR antibody; NR3A1 antibody; Nuclear receptor subfamily 3 group A member 1 antibody
Raised in Rabbit
Species Reactivity Human, Rat
Immunogen Recombinant Human Estrogen receptor protein (10-591AA)
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA, WB, IHC, ChIP
Recommended Dilution
Application Recommended Dilution
WB 1:1000-1:5000
IHC 1:20-1:200
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Native Chromatin Immunoprecipitation(ChIP) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.
Gene References into Functions
  1. Estrogen-induced miR-191 was identified as a direct upstream regulator of DAB2 in ER-positive breast cancer cells. PMID: 29247596
  2. the whole-genome insights carried in this work can help fully understanding biological roles of ER1 in breast cancer. PMID: 30301189
  3. there was a relationship between rs2046210 and rs3803662, and the risk of developing this disease in Vietnamese women. The A allele is the risk allele for both rs2046210 (OR [95% CI] = 1.43 [1.14 - 1.78], P = 0.0015) and rs3803662 (OR [95% CI] = 1.45 [1.16 - 1.83], P = 0.001). We conclude that two polymorphisms, rs2046210 in ESR1 and rs3803662 in TNRC9, are associated with breast cancer risk in the Vietnamese population. PMID: 30078824
  4. that Oestrogen receptor alpha can enhance the odonto/osteogenic differentiation of stem cells from apical papilla via ERK and JNK MAPK pathways PMID: 30069950
  5. No association between polymorphisms in genes encoding estrogen receptors (ESR1 and ESR2) and excreted BPA levels was found in orthodontic patients after bracket bonding. PMID: 29961922
  6. Analysis of the genome-wide ER binding sites identified mutant ER unique recruitment mediating the allele-specific transcriptional program PMID: 29438694
  7. study describes RNF8 as a co-activator of ERalpha increases ERalpha stability via post-transcriptional pathway, and provides a new insight into mechanisms for RNF8 to promote cell growth of ERalpha-positive breast cancer. PMID: 28216286
  8. Reduced expression of ERbeta1 in female ERalpha-negative papillary thyroid carcinoma patients is associated with greater progression of the disease. PMID: 29655286
  9. heterogeneous distribution in deep infiltrating endometriosis PMID: 29383962
  10. ER-alpha36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells PMID: 29481815
  11. This study aimed to determine the presence and localization of oestrogen receptors (ERs), progesterone receptors (PRs), and androgen receptors (ARs) in both healthy and varicose vein wall cells and their relationship with gender. PMID: 30250632
  12. Estrogen receptor-alpha was expressed only in women and showed a positive correlation with the amount of fungi in oral paracoccidioidomycosis, while progesterone receptor was observed in both genders and exhibited no correlation with estrogen receptor-alpha or fungi counting. PMID: 29796757
  13. ERalpha upregulates vinculin expression in breast cancer cells; Loss of vinculin promotes amoeboid features of cancer cells PMID: 28266545
  14. polymorphisms do not predict in vitro fertilization outcome PMID: 29916276
  15. High ESR1 expression is associated with metastasis in breast Cancer. PMID: 29187405
  16. The G/G XbaI genotype of ESR1 gene is associated with breast cancer risk. PMID: 29893332
  17. miR-221 may impair the protective effect of estrogen in degenerated cartilaginous endplate cells through targeting estrogen receptor alpha PMID: 29529124
  18. Results showed that NAT1 and ESR1 expression were increased in primary breast tumor samples compared with normal breast tissue samples, and in ER+ primary breast tumors compared with ER- tumors. Also, NAT1 and ESR1 expression seems to have overlapping regulation. PMID: 29901116
  19. all the patients without these mutations by molecular barcode next-generation sequencing (MB-NGS) were found to have no mutations by ddPCR. In conclusion, MB-NGS could successfully detect ESR1 mutations in cfDNA with a higher sensitivity of 0.1% than conventional NGS and was considered as clinically useful as ddPCR PMID: 28905136
  20. In summary, an association between the presence of the particular genotypes at the three ESR1 polymorphisms (rs2234693, rs6902771, rs7774230) and one ESR2 polymorphism (rs3020449), and the presence of metabolic syndrome in postmenopausal women was found. PMID: 30049354
  21. higher frequency of ESR1 and PIK3CA mutations in the plasma than in the serum in 33 MBC patients; therefore, serum samples should not be considered the preferred source of cfDNA. PMID: 29689710
  22. These results suggest that miR-125a-3p can function as a novel tumor suppressor in ER(+) breast cancer by targeting CDK3, which may be a potential therapeutic approach for TamR breast cancer therapy PMID: 28939591
  23. A major finding of our study is that one out of five (20%) patients with breast cancer BM had a receptor discrepancy between the primary tumor and the subsequent BM, with loss of hormone receptors (ER and/or PR) expression, and gain of HER2 overexpression as the most commonly observed changes PMID: 28975433
  24. Here the authors report a nodal role of IGF-IR in the regulation of ERalpha-positive breast cancer cell aggressiveness and the regulation of expression levels of several extracellular matrix molecules. PMID: 28079144
  25. The associations between PvuII (T>C) and XbaI (A>G) polymorphisms of estrogen receptor alpha (ESR1) gene with type 2 diabetes mellitus (T2DM) or metabolic syndrome (MetS), are reported. PMID: 29883973
  26. The ERalpha gene seems to play a key role in stress urinary incontinence in the premenopausal period. PMID: 29769420
  27. Study reports the first discovery of naturally occurring ESR1 (Y537C) and ESR1 (Y537S) mutations in MCF7 and SUM44 ESR1-positive cell lines after acquisition of resistance to long-term-estrogen-deprivation (LTED) and subsequent resistance to fulvestrant (ICIR). Mutations were enriched with time, impacted on ESR1 binding to the genome and altered the ESR1 interactome. PMID: 29192207
  28. Concomitant high expression of ERalpha36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior and may be used as a predictor for extrathyroid extension, lymph node metastasis, and distant metastasis. PMID: 29368272
  29. Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. PMID: 30061382
  30. Down-regulation of ESR1 gene expression was enhanced by the development of the breast cancer. PMID: 29543921
  31. The aim of the present study was to assess whether fibrosis markers, estrogen receptor (ER)alpha and the stromal derived factor (SDF)1/CXC chemokine receptor type 4 (CXCR4) axis are abnormally expressed in Intrauterine adhesions endometrium. PMID: 29568895
  32. The frequency of alleles and genotypes of polymorphisms FSHR(-29G/A) and ESRI (XbaI A/G) in women with normal to poor response did not have significant correlation. PMID: 29526845
  33. Each estrogen receptor alpha and estrogen receptor beta gene polymorphism might have different impact on postmenopausal osteoporosis risk and bone mineral density in various ethnicities. PMID: 29458346
  34. The results suggest that minor allele A of ESR1 gene is associated with the development of arterial hypertension in men. PMID: 29658078
  35. Study found that tamoxifen treatment induced a decrease in PRMT2 and an increase in ER-alpha36 as well as ER-alpha36-mediated non-genomic effect in MDA-MB-231 breast cancer cell line. PMID: 29620287
  36. ESR1 mutations are not associated with clinical resistance to fulvestrant in breast cancer patients. PMID: 27174596
  37. verexpression of COPS5, through its isopeptidase activity, leads to ubiquitination and proteasome-mediated degradation of NCoR, a key corepressor for ERalpha and tamoxifen-mediated suppression of ERalpha target genes. PMID: 27375289
  38. ESR alpha PvuII and XbaI polymorphisms have no association with ; systemic lupus erythematosus. The combination of the TC/AA and CC/GG genotypes were associated with SLE susceptibility. PMID: 29356461
  39. Estrogen receptor (ER) and progesterone receptor (PR) expression in endometrial carcinoma (EC) were significantly higher than those in the paracarcinoma tissue and control. PMID: 29081408
  40. ESR1 promoter methylation was an independent risk factor and had a high value to predict 28-day mortality from acute-on-chronic hepatitis B liver failure PMID: 29082740
  41. by analyzing different estrogen receptor-alpha(ER-a)-positive and ER-a-negative breast cancer cell lines, we defined the role of CCN5 in the leptin-mediated regulation of growth and invasive capacity. PMID: 29370782
  42. This study identified ESR1 as a direct target of miR-301a-3p. PMID: 29763890
  43. Authors report for the first time the presence of ESR1 methylation in plasma ctDNA of patients with HGSC. The agreement between ESR1 methylation in primary tumors and paired ctDNA is statistically significant. PMID: 29807696
  44. this study reports the development of a novel class of ERa AF2 inhibitors, which have the potential to effectively inhibit ERa activity by a unique mechanism and to circumvent the issue of mutation-driven resistance in breast cancer PMID: 29462880
  45. the P2X7R rs3751143 and ER-alpha PvuII two-locus interaction confers a significantly high susceptibility to osteoporosis in Chinese postmenopausal women. PMID: 28884379
  46. Alcohol consumption may have differential effects on concordant and discordant receptor subtypes of breast cancer. PMID: 29353824
  47. ERalpha and ERbeta mRNA expression was significantly higher (p < 0.05) in tumour tissues relative to their paired normal mucosa and correlated inversely with survival outcome PMID: 29390981
  48. High ESR1 expression is associated with Papillary Thyroid Carcinoma. PMID: 28124274
  49. Oral administration of RAD140 substantially inhibited the growth of AR/ER(+) breast cancer patient-derived xenografts (PDX). Activation of AR and suppression of ER pathway, including the ESR1 gene, were seen with RAD140 treatment. PMID: 28974548
  50. Polymorphism in the ERalpha gene is associated with an increased risk for advanced Pelvic Organ Prolapse. However, polymorphism in the LAMC1 gene does not seem to be associated with such risk. PMID: 29241914
  51. These results indicate an interaction between Brf1 and ER alpha, which synergistically regulates the transcription of Pol III genes. PMID: 28972307
  52. General obesity, indicated by BMI, is more strongly associated with ER+/PR+ subtype, especially among premenopausal women, whereas central obesity, indicated by WHR, is more specific for ER-/PR- subtype, independent of menopausal status. These results suggest that different chemoprevention strategies may be appropriate in selected individuals. PMID: 28912152
  53. Observed significant increase in HSD3B2 and ESR1 transcripts in follicular eutropic endometrium from infertile women with endometriosis may be related to abnormal biological effect of E2 in endometrium, further affecting the development of human embryos. PMID: 29664547
  54. High ERalpha expression is associated with neuroblastoma. PMID: 29374092
  55. Patients with ER(+)/HER2(-) breast cancer were consecutively included for retrospective analysis. The contralateral parenchyma was segmented automatically on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), where upon the average of the top-10% late enhancement was calculated PMID: 28790119
  56. the EMS indicated a more malignant subgroup of the ER- cells by discriminating the chemoresistant ER- cells from the chemosensitive ones. In addition, the classified chemoresistant ER- patients demonstrated worse prognosis. In conclusion, we developed a new method to discriminate subgroups of ER- breast cancer cells. PMID: 29039577
  57. Estrogen receptor percent positive staining is not independently related to breast cancer survival after adjustment for other survival-related factors. ER intensity, in contrast, demonstrates promise for prognostic utility. PMID: 28825224
  58. Estrogen receptor alpha gene polymorphism and vascular complications in girls with type 1 diabetes mellitus. PMID: 28634856
  59. African American patients with breast cancer had worse survival in certain subtype and stage, especially in ER+ breast cancer PMID: 28856481
  60. These studies identify functional EREs in the IKKB promoter and identify IKKB as an ERalpha and NSC35446.HCl-regulated gene, and they suggest that NF-kappaB and IKKB, which were previously linked to antiestrogen resistance, are targets for NSC35446.HCl in reversing antiestrogen resistance. PMID: 28808806
  61. Our findings suggest the possibility for changing the treatment paradigm of patients with ER+HER2-MBC, so a randomized prospective study is warranted to determine the optimum sequence of systemic therapies PMID: 28852946
  62. Results of our present study suggest that both IL-6 and HGF derived from Cancer-associated fibroblasts (CAFs)could contribute to the intratumoral androgen metabolism in ER-negative breast carcinoma patients. PMID: 28831645
  63. estrogen may promote the progression of ER-negative breast cancer by stimulating cancer-associated fibroblasts to secrete SDF-1alpha, which can recruit MDSCs to the tumor microenvironment to exert tumor-promoting effects PMID: 27996037
  64. We demonstrated the presence of a distinct population of ESR1 LBD mutations (E380Q, Y537S, Y537N, Y537C, and D538G) in metastatic tissue and plasma using ddPCR assay. PMID: 29166868
  65. Further study revealed AP000439.3 can regulate expression of CCND1 through enhancing estrogen receptor induction of CCND1. This finding revealed lncRNAs may serve as important effectors of ER in regulation of gene expression and cell phenotype in breast cancer PMID: 29048636
  66. Functional enrichment analysis of DEGs indicated their potential involvement in cancer, and cell activity-related processes. Fifteen overlaps were identified between DEGs and target genes of ESR1, of which 12 were found to be regulated by miRNA. Several known estrogen response genes and novel genes were obtained in this study and they might provide potential therapeutic targets for osteosarcoma PMID: 28849169
  67. The negative correlation between high-grade expression HCMV-IE and hormone receptor expression suggests a role for HCMV in hormone receptor-negative BC tumors, possibly by forcing BC cells into a more aggressive phenotype. PMID: 28595965
  68. Gender differences were observed in ERalpha expression in normal livers. Sub-cellular expression of both ER subtypes is altered in hepatitis C virus (HCV) cirrhosis and HCV-related hepatocellular carcinoma livers as compared to normals and correlates with the expression of inflammatory and oncogenic markers. PMID: 29085224
  69. Report yeast estrogen screen for androgen- and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites. PMID: 29702199
  70. Both buterol and K-1047 (at 10(-6)M) effectively suppressed ERa mRNA gene expression in HeLa cell culture by 83.4 - 9 8.6%. PMID: 29787667
  71. Computational analysis of publicly available microarray datasets of non-small cell lung cancer (NSCC) treated with EGFR targeted therapy identified ESR1 and ELAV1 as the most highly ranked hub genes involved in the NSCLC acquired TKI-resistance. PMID: 29758295
  72. No association was found between the ERalpha gene polymorphisms and Premature thelarche in girls. However, XbaI polymorphisms may contribute to early breast budding. PMID: 28440677
  73. significant prognostic roles of ERalpha, ERbeta and aromatase were discovered in the in prostate cancer specimens of our large multicenter cohort. PMID: 27610593
  74. Sp1 induces leptin expression in cooperation with estradiol action through estrogen receptor alpha PMID: 28864005
  75. this study demonstrated the feasibility of our protocol to detect and monitor ESR1 gene mutations at the single CTC level in MBCs. PMID: 28679775
  76. These data suggest the ERalpha pathway remains active in estrogen-deprived ER(+)/FGFR1-amplified breast cancers. Therefore, these tumors are endocrine resistant and should be candidates for treatment with combinations of ER and FGFR antagonists. Clin PMID: 28751448
  77. ERalpha gene Pvu II polymorphism exerts an important function in the progression of breast cancer and the polymorphism was in significant association with the decrease of breast cancer risk in Asians rather than in Caucasians PMID: 29702977
  78. the performance of the assay, in terms of sensitivity and reproducibility, was studied using undiluted calf serum, and excellent recoveries in the range of 94.7-108% were achieved for the detection of ERalpha in MCF-7 cell lysate. PMID: 28755608
  79. Taken together, these findings demonstrated that Twist was upregulated in high invasion and metastasis cell lines as well as invasive ductal carcinoma (IDC) tissues companioned with downregulated expression of E-cadherin and ER, which provides important clues for the deeper study of breast cancer. PMID: 28901319
  80. results suggest different interactions may occur in a gender and time dependent manner among rs9340799 and other potential factors of depression or predictors of its severity, and influence the development and natural rehabilitation of depression. PMID: 28890035
  81. We found higher nuclear (n)ERalpha and nERbeta5 and lower cytoplasmic (c)ERalpha expression in advanced ovarian cancers. Loss of nERalpha and cERbeta2 expression were observed in clear cell histological subtypes. Positive cERalpha and higher cERbeta1 expression were associated with better disease-free and overall survival. PMID: 28859612
  82. Our results revealed a lack of significant association between ESR1 polymorphisms and calcaneal quantitative ultrasound in a cohort of young adults suggesting that ESR1 gene do not play a major role in the acquisition of bone mass during early adulthood. PMID: 28534210
  83. ERR-alpha is involved in estrogen-mediated obstructive sleep apnea hypopnea syndrome by regulating Myhc-slow expression. PMID: 27250523
  84. We identified calmodulin-like protein 3 (CALML3) as a key sensor of this SNP and a coregulator of ERalpha, which contributes to differential gene transcription regulation in an estrogen and SERM-dependent fashion. Furthermore, using CRISPR/Cas9-engineered ZR75-1 breast cancer cells with different ZNF423 SNP genotypes, striking differences in cellular responses to SERMs and PARP inhibitors, alone or in combination PMID: 28821270
  85. this study found that C allele of rs2234693 and G allele of rs9340799 within ESR1 gene, their interaction between rs2234693 and current smoking were all associated with increased systemic lupus erythematosus risk PMID: 28707126
  86. Laboratory models corroborate intertumor heterogeneity of endocrine response in HGSOC but identify features associated with functional ERalpha and endocrine responsiveness. Assessing ERalpha function (e.g., IGFBP3 expression) in conjunction with H-score may help select patients who would benefit from endocrine therapy. Preclinical data suggest that SERDs might be more effective than tamoxifen PMID: 28073843
  87. SGK3 a kinase transcriptionally regulated by estrogen receptor alpha (ERalpha) in breast cancer, sustains ERalpha signaling and drives the acquired aromatase inhibitors resistance by protecting against endoplasmic reticulum (EnR) stress-induced ERalpha downregulation and cell death through preserving SERCA2b function. PMID: 28174265
  88. Found a striking resemblance in the ERalpha patterns of the two tissue types. PMID: 28167798
  89. polymorphisms not associated with late miscarriage PMID: 28410957
  90. TNBC cells are more resistant to radiation than luminal-type breast cancer cells; ERalpha expression may have major roles in modulating breast cancer cell radiosensitivity PMID: 28570501
  91. Cy-3-glu directly binds to the ligand-binding domain (LBD) of ERalpha36, inhibits EGFR/AKT signaling, and promotes EGFR degradation PMID: 27655695
  92. Our data uncovered an important role of Erbin in regulating hepatocellular carcinoma (HCC) tumorigenesis through inactivating ERalpha-mediated tumor-suppressive signaling, suggesting a new strategy for tamoxifen therapy in HCC by targeting Erbin/ERalpha signaling axis. PMID: 28192186
  93. High concentrations of DINCH urinary metabolites activate human ESR1 receptors. PMID: 29421333
  94. FES PET/CT was a useful biomarker of ER occupancy and/or downregulation in a phase I dose escalation trial of GDC-0810 and helped select the dosage of the ER antagonist/degrader for phase II trials. PMID: 28011460
  95. Hbo1 is another ERalpha coactivator that ubiquitinates ERalpha PMID: 28769019
  96. Patients with Estrogen- and progesterone receptors-positive invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC)have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC PMID: 28365834
  97. Estrogen receptor-Src signaling plays an important role in ER (+) breast cancer, which shows a high potential for bone metastasis. PMID: 28472954
  98. Folate deficiency impaired spermatogenesis and reduced sperm concentration may partly due to inhibiting the expression of the three key molecules (Esr1, Cav1 and Elavl1) essential for sperm production. PMID: 28445960
  99. the association between four ESR1 gene variants, and six ESR2 single nucleotide polymorphisms and breast cancer risk in Tunisian women PMID: 29414691
  100. Ten international pathology institutions participated in this study and determined messenger RNA expression levels of ERBB2, ESR1, PGR, and MKI67 in both centrally and locally extracted RNA from formalin-fixed, paraffin-embedded breast cancer specimens with the MammaTyper(R) test. Samples were measured repeatedly on different days within the local laboratories, and reproducibility was assessed by means of variance comp... PMID: 28490348

Show More

Hide All

Involvement in disease Estrogen resistance (ESTRR)
Subcellular Location Isoform 1: Nucleus, Cytoplasm, Cell membrane, Peripheral membrane protein, Cytoplasmic side, Note=A minor fraction is associated with the inner membrane, SUBCELLULAR LOCATION: Isoform 3: Nucleus, Cytoplasm, Cell membrane, Peripheral membrane protein, Cytoplasmic side, Cell membrane, Single-pass type I membrane protein, Note=Associated with the inner membrane via palmitoylation (Probable), At least a subset exists as a transmembrane protein with a N-terminal extracellular domain, SUBCELLULAR LOCATION: Nucleus, Golgi apparatus, Cell membrane
Protein Families Nuclear hormone receptor family, NR3 subfamily
Tissue Specificity Widely expressed. Isoform 3 is not expressed in the pituitary gland.
Database Links

HGNC: 3467

OMIM: 133430

KEGG: hsa:2099

STRING: 9606.ENSP00000206249

UniGene: Hs.208124

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1